As part of a package supporting its sluggish selling heart failure drug Entresto with payers,Novartis AG released additional data showing that the drug reduces the rate of heart failure hospitalizations and deaths related to the condition compared to the standard of care enalapril.
The FDA's approval of Entresto, which combines the neprilysin inhibitor sacubitril with the angiotensin receptor blocker valsartan, in July 2015 was supported by robust outcomes data in the PARADIGM-HF study,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?